Supporting Information

A general strategy to develop cell membrane fluorescent probes with location- and target-specific fluorogenicities: a case of Zn²⁺ probe with cellular selectivity

Fei Deng,^{a,b} Limin Liu,^a Qinglong Qiao,^{*,b} Chunfang Huang,^a Lu Miao,^b Zhaochao Xu ^{*,b}

^aSchool of Chemistry and Chemical Engineering, Jinggangshan University, Ji'an, Jiangxi 343009, China.

^bKey Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics,

Chinese Academy of Sciences, Dalian 116023, China.

*Corresponding author: Qinglong Qiao and Z. C. Xu, E-mail: <u>qqlqiao@dicp.ac.cn</u> and <u>zcxu@dicp.ac.cn</u>.

1. Materials and Instruments

Unless otherwise stated, all reagents and solvents for synthesis and detection were purchased from commercial suppliers and used without further purification. All water used was from a Millipore water purification system with a minimum resistivity of $18.0 \text{ M}\Omega$ cm.

¹H NMR and ¹³C NMR spectra were recorded on a Bruker 400 spectrometer, using TMS as an internal standard. Chemical shifts were given in ppm and coupling constants (*J*) in Hz. Mass spectrometry data were obtained with a HP1100LC/MSD mass spectrometer and a LC/Q-TOF MS spectrometer. UV-Vis absorption spectra were collected on an Agilent Cary 60 UV-Vis Spectrophotometer. Fluorescence measurements were performed on an Agilent CARY Eclipse fluorescence spectrophotometer (Serial No.FL0812-M018). The distributions of particle size were recorded by the laser particle size analyzer (Zetasizer Nano, Malvern). The TEM imaging was performed by using JEM-2100 high revolution translation electron microscopy.

HT-29 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) containing 10% fetal bovine serum (FBS) under standard culture conditions (atmosphere of 5% CO₂ and 95% air at 37 °C) for 48 h before imaging performed by using ANDOR[™] living cell laser scanning confocal microscope (Revolution WD).

2. Synthesis



Scheme S1. Synthesis of Compounds ZTRS-alkyl.

Compound 1 was synthesized according to the previous literature¹.

Compound 1 (45 mg, 0.1 mmol) and corresponding alkylamine (0.2 mmol, 2 eq.) were dissolved in 20 mL ethanol. After stirred and refluxed for 8h, the solvent was removed under reduced pressure. The crude product was purified by column chromatography with CH_2Cl_2/CH_3OH (50:1) and afforded pure product.

ZTRS-C₈: 40 mg, 70% yield; ¹H NMR (400 MHz, CDCl₃) δ 11.75 (s, 1H), 9.09 (d, J = 8.1 Hz, 1H), 8.68 (d, J = 6.7 Hz, 1H), 8.60 (dd, J = 30.9, 8.0 Hz, 2H), 8.46 (s, 2H), 7.84 (t, J = 7.2 Hz, 1H), 7.62 (s, 2H), 7.32 (d, J = 7.1 Hz, 2H), 7.16 (s, 2H), 4.17 (s, 2H), 4.08 (s, 4H), 3.63 (s, 2H), 1.74 (s, 2H), 1.27 (s, 10H), 0.87 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.80, 164.40, 163.78, 157.67, 149.60, 139.81, 136.73, 132.72, 131.06, 129.09, 128.19, 126.14, 123.54, 123.39, 123.10, 122.72, 117.73, 117.12, 60.67, 59.15, 40.44, 31.83, 29.36, 29.24, 28.16, 27.18, 22.64, 14.11; MS (ESI) m/z: calcd for C₃₄H₃₈N₅O₃ [M+H]⁺ 564.2975, observed 564.2977.

ZTRS-C₁₀: 46 mg, 78% yield; ¹H NMR (400 MHz, CDCl₃) δ 11.75 (s, 1H), 9.09 (d, *J* = 8.3 Hz, 1H), 8.68 (d, *J* = 7.0 Hz, 1H), 8.61 (dd, *J* = 30.3, 8.1 Hz, 2H), 8.46 (s, 2H), 7.84 (t, *J* = 7.6 Hz, 1H), 7.62 (t, *J* = 7.4 Hz, 2H), 7.32 (d, *J* = 7.5 Hz, 2H), 7.15 (s, 2H), 4.21 – 4.14 (m, 2H), 4.08 (s, 4H), 3.63 (s, 2H), 1.74 (s, 2H), 1.26 (s, 14H), 0.87 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.81, 164.42, 163.79, 157.67, 149.60, 139.81, 136.73, 132.74, 131.06, 129.10, 128.19, 126.14, 123.55, 123.38, 123.11, 122.72, 117.74, 117.13, 60.65, 59.13, 40.45, 31.90, 29.58, 29.41, 29.31, 28.17, 27.19, 22.69, 14.14; MS (ESI) m/z: calcd for $C_{36}H_{42}N_5O_3 [M+H]^+$ 592.3288, observed 592.3300.

ZTRS-C₁₂: 45 mg, 73% yield; ¹H NMR (400 MHz, CDCl₃) δ 11.73 (s, 1H), 9.08 (d, J = 8.6 Hz, 1H), 8.69 (d, J = 7.2 Hz, 1H), 8.61 (dd, J = 23.5, 8.2 Hz, 2H), 8.45 (d, J = 4.2 Hz, 2H), 7.89 – 7.78 (m, 1H), 7.62 (td, J = 7.6, 1.6 Hz, 2H), 7.31 (d, J = 7.6 Hz, 2H), 7.15 (dd, J = 7.4, 5.0 Hz, 2H), 4.22 – 4.12 (m, 2H), 4.08 (s, 4H), 3.62 (s, 2H), 1.77 – 1.69 (m, 2H), 1.25 (s, 18H), 0.87 (t, J = 6.7 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.81, 164.42, 163.80, 157.66, 149.61, 139.80, 136.74, 132.73, 131.07, 129.11, 128.19, 126.15, 123.57, 123.40, 123.12, 122.73, 117.77, 117.18, 60.70, 59.14, 40.45, 31.92, 29.65, 29.63, 29.58, 29.42, 29.35, 28.17, 27.19, 22.69, 14.13; MS (ESI) m/z: calcd for C₃₈H₄₆N₅O₃ [M+H]⁺ 620.3601, observed 620.3599.

ZTRS-C₁₄: 48 mg, 74% yield; ¹H NMR (400 MHz, CDCl₃) δ 11.73 (s, 1H), 9.08 (d, J = 8.5 Hz, 1H), 8.68 (d, J = 7.2 Hz, 1H), 8.60 (dd, J = 27.5, 8.3 Hz, 2H), 8.45 (d, J = 4.5 Hz, 2H), 7.88 – 7.80 (m, 1H), 7.62 (td, J = 7.6, 1.4 Hz, 2H), 7.32 (d, J = 7.7 Hz, 2H), 7.15 (dd, J = 6.9, 5.3 Hz, 2H), 4.20 – 4.13 (m, 2H), 4.08 (s, 4H), 3.62 (s, 2H), 1.76 – 1.71 (m, 2H), 1.25 (s, 22H), 0.87 (t, J = 6.7 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.81, 164.41, 163.79, 157.66, 149.60, 139.80, 136.75, 132.72, 131.07, 129.09, 128.19, 126.15, 123.56, 123.40, 123.11, 122.73, 117.76, 117.17, 60.69, 59.14, 40.45, 31.92, 29.70, 29.66, 29.63, 29.58, 29.42, 29.36, 28.17, 27.19, 22.69, 14.14; MS (ESI) m/z: calcd for C₄₀H₅₀N₅O₃ [M+H]⁺ 648.3914, observed 648.3930.

ZTRS-C₁₆: 48 mg, 71% yield; ¹H NMR (400 MHz, CDCl₃) δ 11.76 (s, 1H), 9.09 (d, J = 8.5 Hz, 1H), 8.69 (d, J = 7.2 Hz, 1H), 8.62 (dd, J = 28.3, 8.3 Hz, 2H), 8.45 (d, J = 4.6 Hz, 2H), 7.84 (t, J = 7.9 Hz, 2H), 7.62 (dd, J = 10.9, 4.4 Hz, 2H), 7.31 (d, J = 7.7 Hz, 2H), 7.15 (dd, J = 7.0, 5.2 Hz, 2H), 4.21 – 4.15 (m, 2H), 4.08 (s, 4H), 3.62 (s, 2H), 1.73 (d, J = 7.3 Hz, 2H), 1.25 (s, 26H), 0.88 (t, J = 6.7 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) *δ* 170.79, 164.41, 163.79, 157.68, 149.61, 139.81, 136.72, 132.73, 131.05, 129.10, 128.18, 126.13, 123.55, 123.38, 123.12, 122.71, 117.75, 117.13, 60.68, 59.15, 40.45, 31.93, 29.70, 29.42, 29.36, 28.18, 27.20, 22.70, 14.13; MS (ESI) m/z: calcd for C₄₂H₅₄N₅O₃ [M+H]⁺ 676.4227, observed 676.4246.

ZTRS-C₁₈: according to previous reports.¹

3. Supplementary Figures



Fig. S1 Fluorescence spectra of 10 μ M ZTRS-C₈ in the presence of 30 μ M Zn²⁺ in 20 mM HEPES (pH = 7.4).



Fig. S2 Fluorescence spectra of 10 μ M ZTRS-C₁₀ in the presence of 30 μ M Zn²⁺ in 20 mM HEPES (pH = 7.4).



Fig. S3 Fluorescence spectra of 10 μ M ZTRS-C₁₂ in the presence of 30 μ M Zn²⁺ in 20 mM HEPES (pH = 7.4).



Fig. S4 Fluorescence spectra of 10 μ M **ZTRS-C**₁₄ in the presence of 30 μ M Zn²⁺ in 20 mM HEPES (pH = 7.4).



Fig. S5 Fluorescence spectra of 10 μ M ZTRS-C₁₆ in the presence of 30 μ M Zn²⁺ in 20 mM HEPES (pH = 7.4).



Fig. S6 Fluorescence spectra of 10 μ M ZTRS-C₁₈ in the presence of 30 μ M Zn²⁺ in 20 mM HEPES (pH = 7.4).



Fig. S7 (a) DLS analysis of particle-size distribution of the self-assembled **ZTRS-C**₁₂ (10 μ M) in 20 mM HEPES (pH 7.4). (b) TEM image of the self-assembled **ZTRS-C**₁₂.



Fig. S8 Fluorescence imaging of ZTRS-C₁₂-Zn(II) at the plasma membrane of HT-29 cells. (a) Bright field;
(b) Ex: 405 nm, Slit: 417-477 nm; (c) Ex: 405 nm, Slit: 500-550 nm. Scale bar: 20 μm.





Fig. S11 MS spectrum of $ZTRS-C_8$.



Fig. S12 ¹H NMR spectra of ZTRS-C₁₀ in CDCl₃.



Fig. S13 ¹³C NMR spectra of ZTRS-C₁₀ in CDCl₃.



Fig. S14 MS spectrum of ZTRS-C₁₀.







Fig. S16¹³C NMR spectra of ZTRS-C₁₂ in CDCl₃.







Fig. S18 ¹H NMR spectra of ZTRS-C₁₄ in CDCl₃.



Fig. S19 ¹³C NMR spectra of ZTRS-C₁₄ in CDCl₃.



Fig. S20 MS spectrum of ZTRS-C₁₄.



Fig. S22 ¹³C NMR spectra of **ZTRS-C**₁₆ in CDCl₃.

-200

10

30

20



Fig. S23 MS spectrum of ZTRS-C₁₆.

4. References

1. F. Deng, S. S. Long, Q. L. Qiao and Z. C. Xu, Chem. Commun., 2018, 54, 6157.